Adaptive Biotechnologies Corporation Common Stock (ADPT) — Analysis Summary
Adaptive Biotechnologies Corporation Common Stock (ADPT) has a market cap of $3.95B with year-over-year revenue growth of +54.8%. Net margin stands at -21.5%. The stock trades at a P/E ratio of -61.9.
Key Takeaways
- Revenue changed +54.8% year-over-year
- Net margin of -21.5%
- P/E ratio of -61.9
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, ADPT posted revenue growth of +54.8% and trades at a P/E of -61.9.
Adaptive Biotechnologies Corporation Common Stock (ADPT)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -3.3x — earnings do not cover interest payments
Operating margin at -12.2% — material operating losses
Net margin at -20.7% — significant losses
The latest filing shows negative free cash flow.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
624
Headquarters
SEATTLE, WA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.